1.268SEK+3.76%Mkt Cap: 107.70M SEKP/E: —Last update: 2026-06-01
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which ha…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap107.70M SEK
Enterprise Value80.09M SEK
Revenue (TTM)92.46M SEK
Gross Profit-4.45M SEK
Net Income (TTM)-110.01M SEK
Revenue/Share1.241 SEK
Last Price1.268 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees31
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.40
PEG—
EV/EBITDA-1.61
EV/Revenue0.87
P/S1.12
P/B2.61
EPS (TTM)-0.88
EPS (Forward)-0.13
52W Range
1.1701% of range7.880
52W High7.880 SEK
52W Low1.170 SEK
Profitability
Gross Margin-4.81%
Oper. Margin27.26%
EBITDA Margin-53.85%
Profit Margin-191.45%
ROE-358.13%
ROA-78.13%
Growth
Revenue Growth802.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.22M SEK
CapEx (TTM)—
FCF Margin-82.62%
FCF Yield-70.93%
Net Debt-23.70M SEK
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity0.98
Current Ratio0.88
Quick Ratio0.88
Book Value/Sh0.4690 SEK
Cash/Share0.5980 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 28, 2019
Analyst Consensus
Rating—
Target (Mean)7.500 SEK
Target Range7.500 SEK – 7.500 SEK
# Analysts1
Ownership
Shares Out.84.86M
Float56.07M
Insiders36.32%
Institutions16.83%
Technical
SMA 501.410 (-10.1%)
SMA 2002.028 (-37.5%)
Beta0.53
S&P 52W Chg27.70%
Avg Vol (30d)183.03K
Avg Vol (10d)134.51K
Technical Indicators
RSI (14)37.0
MACD-0.0486
MACD Signal-0.0582
MACD Hist.+0.0096
BB Upper1.376 SEK
BB Middle1.270 SEK
BB Lower1.165 SEK
BB Width16.58%
ATR (14)0.0699 SEK
Vol Ratio (20d)2.32x